Scil Technology GmbH could earn as much as $250 million in up-front and milestone payments from Pfizer Inc. by out-licensing rights to cartilage-derived retinoic acid sensitive protein (CD-RAP), a growth factor preferentially expressed in cartilage tissue. (BioWorld Today) Read More
